Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 1Sarcoma 1Other 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 1012Lung Neoplasms 769Small Cell Lung Carcinoma 159Breast Neoplasms 73Adenocarcinoma of Lung 68Neoplasms 67Colorectal Neoplasms 50NSCLC 49Melanoma 48Stomach Neoplasms 46Pleural Effusion, Malignant 46Pancreatic Neoplasms 45Brain Neoplasms 42Mesothelioma, Malignant 41Ovarian Neoplasms 32Prostatic Neoplasms 31Neoplasm Metastasis 31Head and Neck Neoplasms 30Mesothelioma 28Esophageal Neoplasms 27Carcinoma, Renal Cell 24Carcinoma 24Urinary Bladder Neoplasms 23Lung Diseases 22Colonic Neoplasms 22Thoracic Neoplasms 19Liver Neoplasms 19Thymoma 18Carcinoma, Hepatocellular 18Pleural Effusion 17

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Liver Diseases × Thoracic × Clear all
NCT05662813 2022-12-23

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

West China Hospital

Phase 2 Unknown
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Digestive System Diseases, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡